[18F-fluorodesoxyglucose positron emission tomography/computed tomography in extramedullary multiple myeloma]

Rev Med Chil. 2022 Feb;150(2):199-205. doi: 10.4067/S0034-98872022000200199.
[Article in Spanish]

Abstract

Background: 18F-fluorodesoxyglucose positron emission tomography/ computed tomography (PET-CT) has a high sensitivity and specificity to detect medullary and extramedullary lesions in multiple myeloma (MM).

Aim: To describe the findings of PET-CT in extramedullary multiple myeloma (EMM) at diagnosis and at relapse, and correlate its results with clinical variables, response to treatment and survival.

Materials and methods: Review of medical records and PET-CT reports of 39 patients with multiple myeloma (MM) who had at least one PET-CT study, treated between January 1, 2015, and January 1, 2019 at a clinical hospital.

Results: The Standard Uptake Values for each hypermetabolic lesion were not described in PET-CT reports. Fifteen patients had an EMM and in eight, without a previous clinical suspicion, PET-TC lead to the diagnosis. The mortality rate in the 39 patients with MM was 46%. Sixty seven percent of deaths occurred in patients with EMM.

Conclusions: PET-TC was useful to diagnose EMM. However, a standardization in PETCT reports would be required to unify criteria. As previously reported, EMM had a greater aggressiveness and lower survival.

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Multiple Myeloma* / diagnostic imaging
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18